Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas

Virchows Archiv

Volumn 447, Issue 5, 2005, Pages 816-822

  Feng, Yu Zhen ^a   Shiozawa, Tanri ^a   Horiuchi, Akiko ^a   Shih, Hsien Chang ^a   Miyamoto, Tsutomu ^a   Kashima, Hiroyasu ^a   Suzuki, Akihisa ^a   Nikaido, Toshio ^b   Konishi, Ikuo ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclin A; Endometrial carcinoma; Heterogeneity; Ki 67; p53 mutation

Indexed keywords

CYCLIN A; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; EXON; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; CARCINOMA, ENDOMETRIOID; CYCLIN A; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENES, P53; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEQUENCE ALIGNMENT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 28444476241     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-005-0029-9     Document Type: Article

References (30)

1. Ambros RA, Ross JS, Kallakury BV, Malfetano J, Kim Y, Hwang J, Breese K, Figge J (1995) p53 gene status in endometrial carcinomas showing diffuse positivity for p53 protein by immunohistochemical analysis. Mod Path 8:441-445
2. Barakat RR, Grisby PW, Sabbatini P (2000) Corpus: epithelial tumors. In: Hoskins WJ, Perez CA, Young RC (eds) Principles and practice of gynecologic oncology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 919-959
3. Berchuck A, Boyd J (1995) Molecular basis of endometrial cancer. Cancer 76:2034-2040
4. Crompton NE, Saydan N (1999) Control of the cell cycle. J Neuro-Oncol 22:255-259
5. Dictor M, Ehinger M, Mertens F, Akervall J, Wennerberg J (1999) Abnormal cell cycle regulation in malignancy. Am J Clin Pathol 112:40-52
6. Hartwell LH, Kasten MB (1994) Cell cycle control and cancer. Science 266:1821-1828
7. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296-299
8. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49-53
9. Ito K, Sasano H, Matsunaga G, Sato S, Yajima A, Nasim S, Garret CT (1997) Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 183:318-324
10. Kihana T, Hamada K, Inoue Y, Yano N, Iketani H, Murao S, Ukita M, Matsuura S (1995) Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients. Cancer 76:72-78
11. Koga T, Hashimoto S, Sugio K, Yoshino I, Nakagawa K, Yonemitsu Y, Sugimachi K, Sueishi K (2001) Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation. Int J Cancer 95:232-239
12. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC Jr, Marks JR (1992) Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52:1622-1627
13. Koshiyama M, Konishi I, Fujii S (1998) Pathology, hormonal aspects, and molecular genetics of the two types of endometrial cancer. Cancer J 11:277-283
14. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299-303
15. Ronnett BM, Zaino RJ, Ellenson H, Kurman RJ (2002) Endometrial carcinoma. In: Kurmann RJ (ed) Blaustein's pathology of the female genital tract, 5th edn. Springer, Berlin Heidelberg New York, pp 501-559
16. Lax SF (2004) Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444:213-223
17. Li SF, Shiozawa T, Nakayama K, Nikaido T, Fujii S (1996) Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma. Cancer 77:321-329
18. Luciani MG, Hutchins JR, Zheleva D, Hupp TR (2000) The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. J Mol Biol 300:503-518
19. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S (1992) Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res 52:3674-3678
20. Schneider J, Rubio MP, Rodriguez-Escudero FJ, Seizinger BR, Castresana JS (1994) Identification of p53 mutations by means of single strand conformation polymorphism analysis in gynaecological tumours: comparison with the results of immunohistochemistry. Eur J Cancer 30:504-508
21. Sherr CJ (1994) G1 phase progression: cyclin on cue. Cell 79:551-555
22. Sherr CJ, Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163
23. Shih HC, Shiozawa T, Kato K, Imai T, Miyamoto T, Uchikawa J, Nikaido T, Konishi I (2003) Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor suppressor gene products, Ki-67 and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as poor prognostic indicator. Human Pathol 34:471-478
24. Shiozawa T, Xin L, Nikaido T, Fujii S (1997) Immunohistochemical detection of cyclin A with reference to p53 expression in human endometrial endometrioid carcinoma. Int J Gynecol Pathol 16:348-353
25. Shiozawa T, Nikaido T, Shimizu M, Zhai Y, Fujii S (1997) Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma. Cancer 80:2250-2256
26. Soong R, Knowles S, Williams KE, Hammond IG, Wysocki SJ, Iacopetta BJ (1996) Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 74:562-567
27. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House AK, Iacopetta BJ (1996) Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Human Pathol 27:1050-1055
28. Soslow RA, Shen PU, Chung MH, Isacson C (1998) Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Int J Gynecol Pathol 17:129-134
29. Yamamoto M, Yoshida M, Ono K, Fujita T, Ohtani-Fujita N, Sakai T, Nikaido T (1994) Effect of tumor suppressors on cell cycle-regulatory genes: RB suppresses p34cdc2 expression and normal p53 suppresses cyclin A expression. Exp Cell Res 210:94-101
30. Zhai YL, Nikaido T, Orii A, Horiuchi A, Told T, Fujii S (1999) Frequent occurrence of loss of heterozygosity among tumor suppressor genes in uterine leiomyosarcoma. Gynecol Oncol 75:453-459